Evelo Biosciences Inc

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced that it is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. The interim data readout will include initial safety and efficacy data for the first 113 patients enrolled in the trial. EDP1815 is an investigational oral biologic in development for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19.

Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial news websites. However, in this article we will take a look at their collective moves over the last 5 years and analyze what the smart money thinks of Evelo Biosciences, Inc. (NASDAQ:EVLO) based on that data.

Hedge Funds Are Dumping Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition.

Evelo Biosciences: Clinical Data Coming Soon

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2020 Results - Earnings Call Transcript

-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months ----Advancing newly discovered microbial extracellular vesicles as next-generation SINTAX-based medicines---- Data from Phase 1b trial evaluating EDP1815 in psoriasis spotlighted today at EADV Virtual Congress -- -- Management to host conference call at 8:30 a.m. ET -- CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the third quarter of 2020.

Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights.

Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

–Data expected in 1Q 2021– –Data expected in 1Q 2021–

Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis

– Interim data expected by mid-2021 –

Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session

CAMBRIDGE, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of Julie Carretero as Chief People Officer. In her new role, Ms. Carretero will assume leadership responsibilities for people initiatives, including talent acquisition and employee development, and will be a member of the Evelo Leadership Team.

Evelo Biosciences Appoints Julie Carretero as Chief People Officer

CAMBRIDGE, Mass., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in two upcoming virtual investor conferences in September:

Evelo Biosciences to Participate in Upcoming Investor Conferences in September

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2020 Results - Earnings Call Transcript

– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in moderate psoriasis in the U.S., UK, and EU; trial initiation expected in 3Q 2020 with interim data expected by mid-2021––Additional data from Phase 1/2 trial of EDP1503 in TNBC expected in 4Q 2020––Up to 6 clinical readouts expected over next 6-12 months––Management to host conference call at 8:30 a.m. ET–

Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights

CAMBRIDGE, Mass., July  23, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 30, 2020 to report its second quarter 2020 financial results and discuss business highlights.

Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020

CAMBRIDGE, Mass., July  01, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma (MSS CRC), triple-negative breast cancer (TNBC), and checkpoint inhibitor relapsed tumors, will be presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 - 4, 2020.

Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting

—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust—  —Experimental therapies with potential to prevent and treat complications of COVID-19—  —EDP1815 selected as one of two experimental therapies in the trial—  —EDP1815 has been observed to have favorable tolerability and anti-inflammatory activity in a prior clinical trial—  —Interim data expected in fourth quarter of 2020—

Evelo Biosciences Announces EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial

CAMBRIDGE, Mass., June  16, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd at 11:00 a.m. ET.

Evelo Biosciences to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Evelo Biosciences, Inc. (EVLO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Evelo Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Evelo Biosciences Sees Hammer Chart Pattern: Time to Buy?

Evelo Biosciences Inc (EVLO) CEO Simba Gill on Q1 2020 Results - Earnings Call Transcript

–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020––Selected enteric capsule formulation of EDP1815 for Phase 2 dose ranging trial in psoriasis; trial initiation now expected in 3Q 2020, with interim data in mid-2021––Evelo to continue enrollment in triple-negative breast cancer arm of ongoing Phase 1/2 trial of EDP1503––Management to host conference call at 8:30 a.m. ET–

Evelo Biosciences Reports First Quarter Financial Results and Business Highlights

—Early intervention in hospitalized patients could help prevent progression of disease—   —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial—  —Data expected during 2H 2020—  —Evelo Management to hold conference call today at 8:30 a.m. ET—

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients

Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex

Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H.

CAMBRIDGE, Mass., March  02, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed marked activity on multiple individual systemic markers of inflammation, including interleukin-6 (IL-6) and interleukin-8 (IL-8). IL-6 and IL-8 are well-established mediators of potentially harmful effects in patients with inflammatory diseases and these data support the therapeutic potential of EDP1815 to treat classic inflammatory diseases such as psoriasis.

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2019 Results - Earnings Call Transcript

News for Evelo Biosciences Inc Stock (EVLO)